miRNA control of apoptotic programs: focus on ovarian cancer

miRNAs are a class of small non-coding RNAs that regulate the stability or translational efficiency of targeted mRNAs. miRNAs are involved in many cellular processes, such as differentiation, proliferation and apoptosis, which are altered in cancer through miRNA expression dysregulation. In this article we will discuss recent findings implicating miRNAs in apoptotic program regulation using ovarian carcinoma as an example. Ovarian cancer is the most lethal gynecological malignancy. Most patients are diagnosed with advanced disease that is conventionally managed with surgical resection followed by platinum-based chemotherapy. Killing of cancer cells by chemotherapeutic agents or by triggering cell-surface death receptors relies on activation of apoptotic programs executed through receptor-mediated extrinsic pathways and mitochondrial-dependent intrinsic pathways. Despite an initial good response to chemotherapy, ovarian cancer patients typically experience disease relapse within 2 years of the initial treatment developing resistance even to structurally different drugs. Thus, also in this pathology, tumor cells are able to evade apoptosis using multiple mechanisms, several of which are dependent on miRNA gene regulation.

[1]  Sun-Mi Park,et al.  miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. , 2010, Molecular cell.

[2]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[3]  Charles D. Johnson,et al.  Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. , 2007, Cancer research.

[4]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[5]  R. Burger,et al.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.

[6]  Nicholas T. Ingolia,et al.  Mammalian microRNAs predominantly act to decrease target mRNA levels , 2010, Nature.

[7]  D. Bartel MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[8]  M. Peter Let-7 and miR-200 microRNAs: Guardians against pluripotency and cancer progression , 2009, Cell cycle.

[9]  E. Lengyel Ovarian cancer development and metastasis. , 2010, The American journal of pathology.

[10]  Hiroshi I. Suzuki,et al.  Modulation of microRNA processing by p53 , 2009, Nature.

[11]  S. Fulda,et al.  Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy , 2006, Oncogene.

[12]  R. Agarwal,et al.  Prognostic factors in ovarian cancer: how close are we to a complete picture? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[14]  W. El-Deiry,et al.  Overview of cell death signaling pathways , 2005, Cancer biology & therapy.

[15]  Carlo M Croce,et al.  Apoptomirs: small molecules have gained the license to kill. , 2010, Endocrine-related cancer.

[16]  S. Canevari,et al.  c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome. , 2009, Endocrine-related cancer.

[17]  M. Lotze,et al.  Apoptosis promotes early tumorigenesis , 2011, Oncogene.

[18]  Muller Fabbri,et al.  Modulation of miR-155 and miR-125b Levels following Lipopolysaccharide/TNF-α Stimulation and Their Possible Roles in Regulating the Response to Endotoxin Shock1 , 2007, The Journal of Immunology.

[19]  George A Calin,et al.  MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. , 2009, Cancer research.

[20]  Huan Yang,et al.  MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. , 2008, Cancer research.

[21]  Robert A. Weinberg,et al.  A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis , 2009 .

[22]  G. Perruolo,et al.  Frontiers: PED/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism. , 2009, American journal of physiology. Endocrinology and metabolism.

[23]  J. Cleveland,et al.  Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. , 2003, Cancer cell.

[24]  B. Tsang,et al.  Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro , 2004, Oncogene.

[25]  S. Canevari,et al.  Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment , 2007, Molecular Cancer Therapeutics.

[26]  M. Kurokawa,et al.  Caspases and Kinases in a Death Grip , 2009, Cell.

[27]  Gregory J. Hannon,et al.  microRNAs join the p53 network — another piece in the tumour-suppression puzzle , 2007, Nature Reviews Cancer.

[28]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[29]  H. Hermeking,et al.  Frequent Downregulation of miR-34 Family in Human Ovarian Cancers , 2010, Clinical Cancer Research.

[30]  S. Canevari,et al.  CD95-Mediated Apoptosis Is Impaired at Receptor Level by Cellular FLICE-Inhibitory Protein (Long Form) in Wild-Type p53 Human Ovarian Carcinoma , 2004, Clinical Cancer Research.

[31]  M. Birrer,et al.  Ovarian Cancer: Markers of Response , 2009, International Journal of Gynecologic Cancer.

[32]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[33]  Jing Wang,et al.  Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells. , 2010, Oncology reports.

[34]  Lalit Kumar,et al.  Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.

[35]  A. Safa,et al.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. , 2008, Current cancer drug targets.

[36]  E. Kistner,et al.  Let-7 expression defines two differentiation stages of cancer , 2007, Proceedings of the National Academy of Sciences.

[37]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[38]  Aimee L Jackson,et al.  Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. , 2008, Cancer research.

[39]  Sun-Mi Park,et al.  CD95 promotes tumour growth , 2011, Nature.

[40]  C. Lee,et al.  MicroRNA and cancer – focus on apoptosis , 2008, Journal of cellular and molecular medicine.

[41]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[42]  Joel Greshock,et al.  MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. , 2008, Cancer research.

[43]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[44]  Alicia Algeciras-Schimnich,et al.  Two CD95 tumor classes with different sensitivities to antitumor drugs , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Canevari,et al.  Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. , 2010, The international journal of biochemistry & cell biology.

[46]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[47]  R. Ozols,et al.  Focus on epithelial ovarian cancer. , 2004, Cancer cell.

[48]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[49]  Patricia A. Kruk,et al.  MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN (Cancer Research (2008) 68, (425-433)) , 2008 .

[50]  W. Filipowicz,et al.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? , 2008, Nature Reviews Genetics.

[51]  S. Memarzadeh,et al.  Advances in the management of epithelial ovarian cancer. , 2001, The Journal of reproductive medicine.

[52]  A. Berchuck,et al.  Expression signatures of TP53 mutations in serous ovarian cancers , 2010, BMC Cancer.

[53]  P. Gunaratne,et al.  Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. , 2010, Cancer research.

[54]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[55]  Andreas Villunger,et al.  p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.

[56]  R. Chen,et al.  Regulation of IKKβ by miR-199a affects NF-κB activity in ovarian cancer cells , 2008, Oncogene.

[57]  Mariarosaria Incoronato,et al.  miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. , 2010, Cancer research.

[58]  G. Packham,et al.  MicroRNAs: key players in carcinogenesis and novel therapeutic targets. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[59]  P. Krammer,et al.  Death receptors in chemotherapy and cancer , 2004, Oncogene.

[60]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[61]  Xin Zhang,et al.  p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. , 2008, Cancer research.

[62]  S. Cohen,et al.  microRNA functions. , 2007, Annual review of cell and developmental biology.

[63]  Francesca Meloni,et al.  An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. , 2010, Blood.

[64]  Alice Shapiro,et al.  MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. , 2008, Cancer research.

[65]  J. Wiezorek,et al.  Death Receptor Agonists as a Targeted Therapy for Cancer , 2010, Clinical Cancer Research.

[66]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[67]  C. Croce,et al.  MicroRNAs as regulators of death receptors signaling , 2010, Cell Death and Differentiation.

[68]  T. Kwok,et al.  Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3 , 2008, Apoptosis.

[69]  L. De Cecco,et al.  Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. , 2010, The international journal of biochemistry & cell biology.

[70]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[71]  P. Morin,et al.  MicroRNAs in ovarian carcinomas. , 2010, Endocrine-related cancer.

[72]  G. Gores,et al.  mir-29 regulates Mcl-1 protein expression and apoptosis , 2007, Oncogene.

[73]  M. Gariboldi,et al.  Molecular predictors of response and outcome in ovarian cancer. , 2006, Critical reviews in oncology/hematology.

[74]  B. Tsang,et al.  Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. , 2008, Cancer research.

[75]  D. Green,et al.  Mitochondria and cell death: outer membrane permeabilization and beyond , 2010, Nature Reviews Molecular Cell Biology.

[76]  E. Berns,et al.  MicroRNAs in ovarian cancer biology and therapy resistance. , 2010, The international journal of biochemistry & cell biology.

[77]  Kailai Sun,et al.  MiR‐125b targets BCL3 and suppresses ovarian cancer proliferation , 2011, International journal of cancer.

[78]  Sun-Mi Park,et al.  microRNAs and death receptors. , 2008, Cytokine & growth factor reviews.

[79]  John Calvin Reed,et al.  FAP-1: a protein tyrosine phosphatase that associates with Fas. , 1995, Science.

[80]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.

[81]  I Vergote,et al.  The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. , 2010, Gynecologic oncology.

[82]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[83]  A. Hatzigeorgiou,et al.  A guide through present computational approaches for the identification of mammalian microRNA targets , 2006, Nature Methods.